Abeome is actively looking for partners interested in leveraging the company’s DiSH technology to enable accelerated pre-clinical identification and screening of monoclonal antibody targets. Our strategy involves selectively licensing the platform technology to leading pharmaceutical/biotech companies while concurrently developing our own targets for key therapeutic and diagnostic applications.
Non-exclusive licenses are available for unlimited access and commercialization of the technology, or by specific fields of interest (i.e., research use only, diagnostics, animal health).
Non-exclusive licenses are available for unlimited access and commercialization of the technology, or by specific fields of interest (i.e., research use only, diagnostics, animal health).
For additional information, please contact Mike Wanner at (706) 248-6098.
